MedTrace Logo

Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder

NCT02234024 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-02-07

No results posted yet for this study

Summary

The purpose of this pilot project is to see if a supplemental form of dietary gangliosides can serve as a potential treatment for the rare metabolic condition called ganglioside GM3 synthase deficiency.

Conditions

  • GM3 Synthase Deficiency

Interventions

DIETARY_SUPPLEMENT

Supplementation of dairy-derived concentrated gangliosides.

Sponsors & Collaborators

  • DDC Clinic - Center for Special Needs Children

    lead OTHER

Principal Investigators

  • Heng Wang, MD PhD · DDC Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234024 on ClinicalTrials.gov